Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA5192377
Max Phase: Preclinical
Molecular Formula: C77H98N10O14S2
Molecular Weight: 1451.82
Associated Items:
ID: ALA5192377
Max Phase: Preclinical
Molecular Formula: C77H98N10O14S2
Molecular Weight: 1451.82
Associated Items:
Canonical SMILES: C[C@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1ccccc1)NC(=O)CCN1CCC(Oc2ccccc2Cc2ccccc2)CC1)C(=O)NCCC(=O)N[C@@H](CCCCNC(=O)CCCCC[N+]1=C(/C=C/C=C/C=C2/N(C)c3ccc(S(=O)(=O)[O-])cc3C2(C)C)C(C)(C)c2cc(S(=O)(=O)O)ccc21)C(N)=O
Standard InChI: InChI=1S/C77H98N10O14S2/c1-52(81-74(93)53(2)82-75(94)63(49-55-26-14-9-15-27-55)84-71(90)41-47-86-45-39-57(40-46-86)101-66-30-20-19-28-56(66)48-54-24-12-8-13-25-54)73(92)80-43-38-70(89)83-62(72(78)91)29-21-22-42-79-69(88)33-18-11-23-44-87-65-37-35-59(103(98,99)100)51-61(65)77(5,6)68(87)32-17-10-16-31-67-76(3,4)60-50-58(102(95,96)97)34-36-64(60)85(67)7/h8-10,12-17,19-20,24-28,30-32,34-37,50-53,57,62-63H,11,18,21-23,29,33,38-49H2,1-7H3,(H9-,78,79,80,81,82,83,84,88,89,90,91,92,93,94,95,96,97,98,99,100)/t52-,53-,62-,63-/m0/s1
Standard InChI Key: GYSHDTUCNXCSMQ-MYQIIKOESA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 1451.82 | Molecular Weight (Monoisotopic): 1450.6705 | AlogP: | #Rotatable Bonds: |
Polar Surface Area: | Molecular Species: | HBA: | HBD: |
#RO5 Violations: | HBA (Lipinski): | HBD (Lipinski): | #RO5 Violations (Lipinski): |
CX Acidic pKa: | CX Basic pKa: | CX LogP: | CX LogD: |
Aromatic Rings: | Heavy Atoms: | QED Weighted: | Np Likeness Score: |
1. Kok ZY, Stoddart LA, Mistry SJ, Mocking TAM, Vischer HF, Leurs R, Hill SJ, Mistry SN, Kellam B.. (2022) Optimization of Peptide Linker-Based Fluorescent Ligands for the Histamine H1 Receptor., 65 (12.0): [PMID:35734860] [10.1021/acs.jmedchem.2c00125] |
Source(1):